TMCnet - World's Largest Communications and Technology Community



Research and Markets: Vaccine Partnering Terms and Agreements - 2014 Report
[January 10, 2014]

Research and Markets: Vaccine Partnering Terms and Agreements - 2014 Report

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Vaccine Partnering Terms and Agreements" report to their offering.

The report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report contains over 1,100 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Vaccine Partnering Terms and Agreements includes:

- Trends in vaccine dealmaking in the biopharma industry since 2007

- Analysis of vaccine deal structure

- Access to headline, upfront, milestone and royalty data

- Case studies of real-life vaccine deals

- Acces to over 1,100 vaccine deal documents

- The leading vaccine deals by value since 2007

- Most active vaccine dealmakers since 2007

- The leading vaccine partnering resources

In Vaccine Partnering Terms and Agreements, the available contracts are listed by:

- Company A-Z

- Headline value

- Stage of development at signing

- Deal component type

- Therapy target

- Specific technology type

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Questions Answered

- What are the precise vaccine rights granted or optioned?

- What is actually granted by the agreement to the partner company?

- What exclusivity is granted?

- What is the payment structure for the deal?

- How are sales and payments audited?

- What is the deal term?

- How are the key terms of the agreement defined?

- How are IPRs handled and owned?

- Who is responsible for commercialization?

- Who is responsible for development, supply, and manufacture?

- How is confidentiality and publication managed?

- How are disputes to be resolved?

- Under what conditions can the deal be terminated?

- What happens when there is a change of ownership?

- What sublicensing and subcontracting provisions have been agreed?

- Which boilerplate clauses does the company insist upon?

- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

- Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

- Abbott

- Alnylam Pharmaceuticals

- Astellas

- AstraZeneca

- Bavarian Nordic

- Baxter International

- Bayer

- BioCryst Pharmaceuticals

- Biogen Idec

- Biota Holdings

- Boehringer Ingelheim

- Bristol-Myers Squibb


- Daiichi Sankyo

- Eisai

- Elan

- Emergent BioSolutions

- Genmab

- Gilead Sciences

- GlaxoSmithKline

- Immunomedics

- Johnson & Johnson

- Kyowa Hakko Kirin

- Merck & Co

- Merck KGaA

- Mitsubishi (News - Alert) Tanabe

- Morphosys

- Novartis

- Pfizer

- Purdue Research Foundation

- Ranbaxy Laboratories

- Roche

- Shionogi

- Spectrum (News - Alert) Pharmaceuticals

- Takeda Canada

- Teva

For more information visit

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy